Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male, or non-pregnant, non-breastfeeding female~* No previous history of virological failure~* No previous exposure to non-nucleoside reverse transcriptase inhibitors or integrase inhibitors~* No previous history of intolerance to lamivudine~* At least 2 documented plasma HIV-1 RNA \<50 copies/mL and no HIV-1 \>50 copies/mL in the 12 months before screening~* Receiving the same protease inhibitor/ritonavir plus tenofovir/emtricitabine combination for at least the 6 months before screening~* Has no major International Antiviral Society (IAS)-USA mutations on genotype testing performed before starting antiretroviral treatment~* Sexually-active participants and their partners of child-bearing potential agree to use a medically acceptable method of contraception from 2 weeks before Day 1 and for at least 6 months after the last dose of study drug (postmenopausal women are not required to use contraception; sexually-active male participants with a female partner of child-bearing potential must provide written informed consent to information regarding any pregnancy)~Exclusion Criteria:~* Positive for hepatitis B surface antigen (HBsAg+) or anticipated need for hepatitis C virus treatment~* Liver cirrhosis~* Has a history of diabetes mellitus, defined as initiation of antidiabetic treatment or verification of diabetes in a case report form~* Has any cancer, excluding stable Kaposi Sarcoma~* Allergy or sensitivity to the investigational product or excipients~* Female participant who is nursing~* Female participant who is pregnant or intends to become pregnant~* Has an active Acquired Immunodeficiency Syndrome (AIDS)-defining event except stable Kaposi Sarcoma or HIV Wasting Syndrome~* Received any investigational drug within 30 days before screening~* Participated in any other clinical trial within 30 days before signing informed consent for the current trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Raltegravir plus Nevirapine plus Lamivudine (Type: EXPERIMENTAL): Raltegravir 400 mg oral twice daily for 96 weeks; plus nevirapine 200 mg oral once daily for 14 days followed by nevirapine 200 mg oral twice daily, plus lamivudine 150 mg oral twice daily for 96 weeks
- Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine (Type: ACTIVE_COMPARATOR): Tenofovir/emtricitabine 300/200 mg oral once daily plus 1) lopinavir/ritonavir 400/100 mg oral twice daily or 800/200 mg oral once daily, or 2) atazanavir/ritonavir 300/100 mg oral once daily, or 3) darunavir/ritonavir 800/100 mg oral once daily or 600/100 mg oral twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues